may lead to therapies tailored to individual patients (5-9 ).
We recently demonstrated that the number of CTCs mirrors disease progression in hormone-refractory prostate cancer (HRPC) (10 ) . This assay was based on immunomagnetic enrichment of epithelial cells in concert with multiparameter flow cytometry (9, 10 ) . This system allowed us to phenotype CTCs for HER-2 protein in breast cancer patients (9 ) . Morphologic characterization of CTCs was achieved with an automated fluorescent microscope (11, 12 ) .
In this study we expand the analytical capabilities of immunomagnetically enriched CTC enumeration to include molecular biological characterization of CTCs. Al-though immunomagnetic enrichment of CTCs can provide a four to five log reduction in leukocytes, the typical range for CTC-to-leukocyte ratios is 1-10 CTCs/10 3 -10 4 leukocytes. The low number of CTCs and the leukocyte carryover during the CTC enrichment process pose significant detection restrictions in terms of the signal-tonoise ratio, which constrains the choice of genes and gene expression profiling methods. The low CTC number thus requires preamplification of the entire mRNA library to analyze a multigene reverse transcription-PCR (RT-PCR) panel without compromising the sensitivities of individual marker genes. Here we show that detection of the RNA encoded by numerous genes in CTCs is feasible. The method entails constructing and synthesizing an antisense RNA (aRNA) library from mRNA extracted from immunomagnetically enriched CTCs, which permits the analysis of numerous genes through RT-PCR. We investigated the expression of 37 genes, including the prostatetissue-specific genes prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and human glandular kallikrein 2 (HK2). Also included were prostatecancer-specific genes such as hepsin (HPN) and prostatespecific gene with homology to G protein receptor (PSGR), as well as therapy-relevant genes such as androgen receptor (AR), HER-2, BCL-2, multidrug resistance gene (MDR1), and epidermal growth factor receptor (EGFR). The ability to quantify, phenotype, morphologically image, and now profile the gene expression of CTCs allows improved biological characterization of HRPC in real time and may help expedite the development of effective patient-specific therapies.
Materials and Methods patients
Blood from 9 patients with prostate cancer (CaP) and 13 healthy volunteers (7 males and 6 females) was drawn into two 10-mL EDTA-containing Vacutainer Tubes (Becton Dickinson) and pooled. Of the nine patients, eight had HRPC with a sustained increase in PSA and/or a positive bone scan. The single hormone-sensitive patient initially presented with a positive bone scan, but he subsequently had a sustained complete response to androgen ablation with a negative bone scan and a PSA of 0.1 g/L. The male controls were 27-73 years of age (mean, 45 years), and the female controls were 27-61 years of age (mean, 39 years). The patients ranged in age from 60 to 81 years (mean, 74 years). The treatments, bone scan status, PSA concentrations, and CTC counts are given in Table 1 . Of the nine patients, two had five longitudinal blood samples, one had four samples, three had two samples, and three had single samples. All participants signed an institutional informed consent form.
cell lines
The breast cancer cell line SKBR-3 and prostate cancer cell line LNCaP were cultured in RPMI-1640 supplemented with 100 mL/L fetal calf serum.
immunomagnetic sample preparation
Immunomagnetic enrichment of epithelial cells has been described in detail previously (10, 11 ) . Blood samples were divided into two 7.5-mL aliquots processed within 3 h. Briefly, the enrichment step involves adding magnetic nanoparticles coated with a monoclonal antibody with affinity for epithelial cell adhesion molecule (EpCAM) to a 7.5-mL blood sample, incubating the sample, and placing the tube inside a magnetic separator for immunomagnetic separation of the magnetically labeled CTCs. After separation, the enriched CTCs from one tube are used for RNA extraction, and the second tube is used for CTC enumeration.
ctc enumeration
Enriched cells containing CTCs and contaminating leukocytes were stained with pan-anti-cytokeratin-phycoerythrin to detect epithelial cells, a pan-leukocyte marker (anti-CD45 PerCP; Becton Dickinson), and a nucleic acid dye as described previously (10 P-end-labeled with polynucleotide kinase in ExpressHyb Hybridization Solution (cat. no. 8015-1; Clontech) at 42°C for 2 h, according to the manual for the probes. The probed blot was phosphorimaged on a Cyclone PhosphorImager (Packard Instruments) to determine RNA integrity (18S:28S ratio) and total mass relative to high-integrity total RNA calibrators of known mass (0.25, 0.5, 1.0, and 2.0 ng) run in parallel on the blot. The RNA mass from each sample was defined as the 7.5-mL blood-donorequivalent for sample normalization by volume. The detailed procedure for RNA isolation can be found in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol50/ issue5/.
transcript library preamplification by smartarna
The SMART-aRNA procedure uses the switching mechanism at the 5Ј termini of RNA templates in the SMART TM PCR cDNA Synthesis Kit (cat. no. K1052-1; Clontech). The SMART-aRNA procedure was used because it simplifies the second-strand synthesis for constructing doublestranded cDNA libraries. The SMART primer was modified on the 3Ј terminus to contain a functional T7 RNA polymerase promoter for subsequent aRNA amplification reactions. In addition, a minimum number of PCR cycles was used to boost cDNA library mass before T7 RNA polymerase linear amplification with minimal negative effects on mRNA library representation. The remaining 80% of each RNA sample was used in the synthesis of first-strand cDNA followed by 10 cycles of PCR performed according to the SMART Uses Manual (part no. PT3041-1; Clontech) along with the following three modifications:
• The first-strand reaction used a total volume of 10 L (1 L of SuperScript II; cat. no. 18064-022; Invitrogen), and the volume of the SMART II oligonucleotide (10 M) was reduced from 1.0 to 0.2 L per reaction tube. This reduced the cost per reaction without compromising yield or representation.
• An oligo(dT) primer containing the following T7 RNA polymerase promoter sequence (5Ј-TCTAGTCGACGG-CCAGTGAATTGTAATACGACTCACTATAGGGCGT-TTTTTTTTTTTTTTTTTTTT-3Ј) on its 5Ј terminus was substituted in an equimolar amount for the corresponding oligo(dT) primer provided as the "cDNA synthesis (CDS) primer" in the reagent set. This enabled the incorporation of T7 promoter at the 3Ј terminus of all cDNA.
• For assembly of the cDNA PCR amplification reactions, the entire 10-L first-strand reaction was added to 40 L of Advantage 2 PCR master mixture (cat. nos. K1910-y and K1052-1; Clontech). Advantage 2 PCR master mixture reagents were maintained in the proportions given in the instruction manual along with the addition of a second PCR primer (1 L of a 10 M stock) that was homologous to the 5Ј portion of the dT-T7 replacement primer composed of the sequence 5Ј-TCTAGTCGACGGCCAGTGAATT-3Ј.
We then performed 10 cycles of PCR amplification with the following cycling profile: 95°C for 1 min followed by 10 cycles of 95°C for 5 s, 65°C for 15 s, and 68°C for 6 min, with a final 20-min step at 72°C. The PCR reaction mixture was processed through a Sephadex G-50 Quick Spin column (TE; cat. no. 1 523 023; Roche Diagnostics), and the eluate was concentrated under reduced pressure to 7 L. T7 aRNA polymerase amplification reactions using the AmpliScribe reagent set (cat. no. AS2607; Epicenter Technologies) were assembled and incubated at 37°C for 12-16 h. The aRNA was purified by use of 180 L of TRIzol with 1.25 L of coprecipitate added to the aqueous phase, and the pellet was resuspended in 10 L of RNase-free water. We denatured 20% (2 L) of the purified aRNA reaction mixture, using 1 L of 6ϫ formamide-formaldehyde and 3 L of water at 65°C for 15 min. The denatured mixture was electrophoresed (2% agarose gel) along with 50 and 500 ng of RNA molecular weight and mass calibrators (0.24 -9.5 Kb RNA ladder; 1 g/L; cat. no. 15620-016; Invitrogen) for 15 min at 5 V/cm and then was stained with SYBR Gold (cat. no. S-11494; Molecular Probes). The quality and quantity of the aRNA library were determined by AlphaImager densitometry relative to calibrators by use of AlphaEase Total RNA mass/7.5-mL sample ϫ0. 015 3 ϭ 1 donor-equivalent RNA where "Total RNA mass/7.5-mL sample ϫ 0.015" indicates that mRNA accounts for 1.5% of total RNA mass; and "3" indicates that the mean molecular weight of the aRNA library ϳ3-fold less than that of the total mRNA. The detailed procedure for transcript library preamplification by SMART-aRNA can be found in the online Data Supplement.
multigene rt-pcr analysis
We reverse-transcribed 25 ng of aRNA in a 10-L reaction volume containing 50 ng of random 9mer primers, 1 L of SuperScript (Invitrogen), and 2 L of 5ϫ reaction buffer (Invitrogen); the mixture was incubated at 25°C for 10 min, 37°C for 10 min, 42°C for 20 min, and 50°C for 60 min. For PCR, cDNA was then diluted to 1 donorequivalent/L. Ten donor-equivalents (10 L) per cDNA sample (mass range, 50 -1300 pg) were used in each subsequent 50-L PCR reaction containing 1 U of platinum Taq (Invitrogen). We generated individual PCR kinetics curves from single PCR reaction tubes by pausing the thermocycler at 31, 35, and 40 cycles and aliquoting 15 L to a separate tube for subsequent gel densitometry analysis. The PCR program was as follows in a PE-9700 thermal cycler: 1 min at 95°C, followed by 40 cycles of 95°C for 15 s, 65°C for 15 s, and 72°C for 1 min, followed by 20 min at 72°C. RT-PCR samples were electrophoresed on 2% agarose gels (5 V/cm for 20 min) in parallel with DNA size and mass calibrators (Low Range Quantitative DNA ladder; cat. no. 12373-031; Invitrogen), stained with ethidium bromide (5 g/L), and analyzed by an AlphaImager Gel Documentation and Image Analysis System with AlphaEase TM software, Ver. 5.04, to determine molecular weight and spot densitometry.
primer design
All gene-specific RT-PCR primer sets were designed to amplify within the last 500 nucleotides of each transcript's 3Ј-untranslated region upstream from poly(A) and optimized to give single bands of specific molecular weights (Table 2) . Sequence identity was confirmed by internal oligoprobe blot hybridization.
scaling of rt-pcr results relative to an external calibration curve
Relative gene expression values of 0, 1, 2, 3, and 4 were assigned to samples based on comparisons of kinetics curve band intensities relative to an external calibration curve, prepared in parallel, of cytokeratin 19 (CK19) cDNA, as shown in Fig. 1 . The lower limit of RT-PCR detection was evaluated with a CK19 in vitro-transcribed RNA construct (CK19 cRNA) that contained the 3Ј-most 800 nucleotides of GenBank accession no. NM_002276.
lower limit of detection for the smart-arna preamplification and rt-pcr analysis system
The lower limit of mRNA transcript detection for the entire SMART-aRNA preamplification and RT-PCR analysis system was determined in triplicate with a test sample set. The test RNA samples were composed of a tissue culture cell line RNA containing predetermined copy numbers of PSA, PSMA, CK19, AR, and HPN mRNA, which was added to a background of 2000 leukocyteequivalents of total RNA. The test set was then subjected to SMART-aRNA preamplification and RT-PCR analysis.
Results

ctc enumeration and rna analysis
In the blood samples from 13 healthy donors, the number of leukocytes carried over in the immunomagnetic selection ranged from 655 to 5560 (median, 1450; mean, 1759). In the 23 samples from CaP patients, the number of leukocytes carried over ranged from 813 to 92 000 (median, 4350; mean, 12 300). The events that were classified as CTCs in blood samples from the control group ranged from 0 to 4 CTCs/7.5 mL [mean (SD), 0.8, (1.2)]. In blood samples from HRPC patients, the CTCs ranged from 4 to 283/7.5 mL (median, 89; mean, 87; Table 1 ). The total RNA from the 13 healthy donors as assessed by Northern blot had a mean 28S:18S band ratio of 1.4 (range, 1.2-1.8) with a mean yield of 3.5 ng (range, 0.8 -11.12 ng). In CaP patients, this ratio was 1.2 (range, 0.6 -1.8) with a mean yield of 7.2 ng (range, 0.8 -35.12 ng). All samples subsequently produced aRNA libraries with masses closely proportional to the starting total RNA values.
characterization of smart-arna library amplification
The modified aRNA amplification method produced libraries with a mean 10 000-fold yield above the original mRNA mass. The original amount of mRNA was estimated to be 1.5% of the total RNA mass. The median transcript length of the libraries was 600 nucleotides (range, 550 -800 nucleotides). Individual transcript lengths within each library ranged from 300 to 3000 nucleotides. We investigated the distortion effect of this modified aRNA amplification method on the relative mRNA abundance by comparing the expression of CK8, CK19, mammaglobin 1 (MGB1), mammaglobin 2 (MGB2), prolactin-inducible protein (PIP), EpCAM, PSA, and PSMA in RNA libraries obtained from tumor cell lines with and without amplification. As shown in Fig. 2 , there was no dropout of any mRNA target sequence attributable to the SMART-aRNA method. In addition, we saw no dramatic differences in band intensity ratios for all eight mRNA sequences when we compared the amounts of RNA after 32 and 40 PCR cycles.
We assessed the effect of the SMART-aRNA preamplification procedure on the lower limit of detection for RT-PCR with a model system mimicking immunomagnetically enriched CTC samples. In triplicate samples, the combination of SMART-aRNA followed by RT-PCR amplification showed reproducible detection of mRNA from all six targets-PSA, PSMA, AR, HPN, EpCAM, and CK19-down to at least 50 transcripts (data not shown).
Clinical Chemistry
We evaluated the lower limit of detection for RT-PCR with in vitro-transcribed CK19 cRNA. The results from 10 separate RT-PCR reactions showed that the CK19 cRNA was reproducibly detectable in 10 of 10 separate reactions down to 25 molecules of RNA (data not shown). RT-PCR contamination controls containing all components except cDNA sample template were run in parallel with each batch and did not show any detectable signals, indicating the absence of crossover and carryover contamination during these studies.
multigene rt-pcr profiling of smart-arna from samples from healthy donors immunomagnetically enriched for ctcs An external calibration curve constructed with CK19 cDNA was run in parallel with samples. The band inten- sities from the calibration curve were used to assign relative gene expression values of 0, 1, 2, 3, and 4 to the samples shown in Fig. 1 . All blood samples contained leukocytes carried over from the CTC enrichment process. The ␣ 1 -globin gene was found to be specifically expressed in leukocytes and was therefore used as the functional system control for indicating successful RNA processing and amplification. All 36 samples gave gene expression values Ͼ4 for ␣ 1 -globin (Table 2 ; data not shown for patient samples). Expression of 38 genes was assessed in the aRNA libraries of the 13 healthy controls. The expression profiles of these genes and the aRNA-RT-PCR design characteristics are listed in RT-PCR for CK19 was performed on dilutions of CK19 cDNA containing 25 000, 2500, 250, and 25 copies, each added to 2 ng of leukocyte total RNA. Reactions were run for 31, 35, and 40 cycles, and typical band intensities corresponding to CK19 cDNA copy number are shown here. For multigene RT-PCR scaling, comparisons were made to the CK19 cDNA external calibration curve run in parallel, and approximate 10-fold differences in relative gene expression were assigned: 0, nondetectable; 1, ϳ25-50 copies; 2, ϳ250 -500 copies; 3, ϳ2500 -5000 copies; 4, Ͼ25 000 copies. serial ctc and mrna profiles during treatment of three hrpc patients
Longitudinal patient profiles of CTC counts and mRNA expression for PSA, PSMA, AR, and HPN in blood samples drawn over the course of 18 -26 weeks from three patients with HRPC are shown in Fig. 4. Patient 1 (Fig.  4A ) was treated with long-term hormone ablation (Lupron). Patients 2 and 3 (Fig. 4 , B and C, respectively) were also on long-term Lupron treatment and, in addition, were begun on chemotherapy consisting of Taxane/estramustine. The CTC values changed by ϳ10-fold for all three patients during this survey period, and some trends were noted as follows. For the patient treated with Lupron alone (Fig. 4A) , who had four longitudinal samples drawn at 0, 5, 10, and 18 weeks, we observed a dramatic progressive increase in CTC counts from 45 up to 300 during the survey period. In contrast, the two patients treated with Lupron and adjuvant chemotherapy (Fig. 4 , B and C) showed a significant increase in CTC counts followed by a decrease. For the patient in Fig. 4C , we observed a dramatic increase in CTCs after the chemotherapy regimen was discontinued. mRNA concentrations during serial sampling showed that PSMA expression paralleled CTC changes, whereas PSA expression remained high throughout the survey period. The amounts of AR mRNA in the patients represented in panels A and B of Fig. 4 remained relatively constant. AR expression was detected in blood draws from the patient (Table 1) . With the unique identification numbers the multigene profile can be traced. The x axis shows 9 of the 13 genes that did not show any leukocyte background in Table 2 represented in Fig. 4C only during treatment with Taxane/estramustine and was not detected before or after treatment. We detected a dramatic change in HPN mRNA in the patients represented in panels B and C of Fig. 4 , from high expression when the patients were untreated to complete elimination during the Taxane/estramustine treatment. HPN expression fluctuated in the blood samples from the patient represented in Fig. 4A . The changes in mRNA concentrations were independent of the number of CTCs and leukocytes.
Discussion
Clinical endpoints to measure HRPC disease burden have traditionally been limited to survival. Recently, serum PSA has gained some acceptance as a viable endpoint (13 ) , and positive signals for PSA RT-PCR, signifying the presence of CTCs in HRPC, have also been suggested to predict survival (3 ) . We have shown that the quantity of CTCs trends with metastatic disease progression in a manner that is independent of PSA concentration in select cases (10 ) . Our goal in this study was to determine the feasibility of profiling gene expression in CTCs with the ultimate aim of better characterizing advanced CaP biology. However, a substantial enrichment of CTCs over leukocytes is needed to overcome signal-to-noise factors. A modified T7 RNA polymerase preamplification method (SMART-aRNA) was engineered to produce aRNA CTC libraries from immunomagnetically enriched CTCs targeting the epithelial cell surface antigen EpCAM. The preamplification of mRNA produced a 10 000-fold increase in mRNA, whereas the representation of genes in the aRNA library was not compromised compared with the native, unamplified mRNA library (Fig. 2) . mRNA was detectable down to amounts as low as 50 molecules (data not shown). The small linear dynamic range obtained with the semiquantitative RT-PCR detection system used in this study can be readily improved by use of "real-time" quantitative RT-PCR. This approach to profile mRNA gene expression in the CTCs present in 7.5 mL of blood is limited by a background of 10 3 -10 4 leukocytes. The unavoidable leukocyte carryover translates into significant signal-to-noise restrictions that limit the genes that can be adequately evaluated. For example, the expression of p53, TS, MRP, HER-2, and BCL-2 in leukocytes precludes unambiguous detection of their overexpression in CTCs. It might, however, be possible to develop a method to subtract the leukocyte mRNA background from patient-specific CTCs based on the leukocyte profile obtained from patient-matched CTC-depleted leukocyte fractions or CTCs enriched from healthy donors. Alternatively, the leukocyte background can be significantly reduced by use of fluorescence-activated cell sorting. However, cell sorting inevitably leads to losses of CTCs and is practical only in a research setting.
Another method to overcome this limitation of gene expression is to assess the amount of mRNA through protein production. For example, although HER-2 mRNA analysis is not possible in immunomagnetically enriched CTCs because of the background expression of HER-2 mRNA in leukocytes, the production of HER-2 protein by CTCs has been assessed successfully in breast cancer patients (9 ) . Conversely, not all proteins can be assessed on CTCs. Some secreted proteins, such as PSA, migrate out of the CTCs during permeabilization and can no longer be detected. Hence the limitations of CTC detection by flow cytometry or microscopy can be overcome by complementary aRNA analysis. This was illustrated in one of the nine patients. Case 9 was the only androgensensitive case in this study and had 30 CTCs/7.5 mL of blood, which was confirmed morphologically by fluorescence microscopy. However, these CTCs were negative on RT-PCR for PSA, PSMA, HK2, and PSGR, suggesting that they might express different genes reflecting their different disease biologies. However, at this time we cannot rule out the possibility that these CTCs might not be derived from the prostate. mRNA concentrations for Muc1 and Trop2A were higher in samples from patients than in control samples, suggesting that these CTCs could be derived from epithelial tissue representing another clinically occult neoplasm. CTCs ranged from 4 to 283/7.5 mL blood for 23 specimens from 9 prostate cancer patients. In contrast the CTC range in the 13 control cases was 0 -4 CTCs/7.5 mL (mean, 0.8). One of the epithelial cell-specific genes (CK19, EpCAM, or Muc1) was expressed in all patient samples, whereas 21 of 23 samples from 8 of 9 patients showed expression of one of the prostate-specific genes (PSA, PSMA, or HPN). Expression of these prostate-tissue-specific genes was completely absent in controls. The relative expression of CK19, PSA, and PSMA was comparable to the values reported in the literature (14, 15 ) . For example, the proportion of samples that were positive for HK2 expression (30%) was similar to the 25% reported by Ylikoski et al. (16 ) . Although the proportion of samples in which PSGR expression was detectable (2 of 23; 9%) may be lower than previously published values, it is possible that PSGR is expressed in higher amounts in CTCs of patients with hormone-naive prostate disease (17, 18 ) . HPN has not been studied extensively in patients with HRPC, and the proportion of samples with detectable expression (57%) in this report suggests that this may be a viable drug therapy target (19 ) . Moreover, the efficacy of anti-HPN agents may be assessed by their ability to decrease HPN expression in CTCs. EGFR was expressed in only 17% of the specimens, which is low compared with the 57% reported in prostate samples from 16 patients with HRPC (20 ) . This discrepancy may be attributable to several factors, including differential EGFR expression in CTCs vs prostate cancer cells within the organ of origin. We found a similar discrepancy in Topo2A expression (22%) (21 ) . The expression of AR in 70% of the samples is in agreement with the results reported by Linja et al. (22 ) , who found a correlation between androgen independence and high AR expression in 13 patients with HRPC. Many hormone-dependent features are known to be common to breast and prostate cancers, which may explain the observed expression of PSA in breast cancer (23 ) and the first reported expression of the breast-specific genes MGB1 and MGB2 in CTCs from CaP patients.
Expression of the AR, HPN, PSMA, and PSA genes in CTCs was surveyed serially over an ϳ8-to 26-week period in three patients (Fig. 4) . Two of the three patients had received chemotherapy. The results shown in Fig 4 demonstrate that the CTC counts reflect disease progression more accurately than semiquantitative PSA and PSMA RT-PCR results, which showed uniformly high expression throughout the monitoring period. This may be limited by the semiquantitative RT-PCR assay used in this study, however, because a relative gene expression score of 4 for PSA and PSMA can not be differentiated from saturation in this detection system. Our data imply that previous PSA RT-PCR studies that attempted to predict survival may have been hampered by an inability to differentiate between high and low CTC counts. The results further support research into AR as a therapeutic target because the amount of AR expression was sustained and found to be minimally affected by chemotherapy.
In conclusion, we believe that gene expression profiling of CTC mRNA is feasible. Our data further validate that the immunomagnetically enriched CTCs enumerated by flow cytometry or fluorescence microscopy originated from the CaP tissue. The prostate CTCs exhibited heterogeneous expression of genes such as PSA, PSMA, and HPN. In the HRPC cases studied, AR expression appeared to be consistently increased, suggesting AR as a viable therapeutic target. The ability to quantify, phenotype, morphologically examine, and now molecularly profile CTCs could lead to improved characterization of HRPC and ultimately to development of more effective, personalized novel therapeutic strategies.
